[1] [1] BRAY F, FERLAY J, SOERJMATARAM I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394-424.

[2] [2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019［J］. CA: A Cancer Journal for Clinicians, 2019, 69(1): 7-34.

[3] [3] ZHANG S K, XU H F, ZHANG L Y, et al. Cervical cancer: epidemiology, risk factors and screening［J］. Chinese Journal of Cancer Research, 2020, 32(6): 720-728.

[4] [4] LEEMANS C, ZWALM M C H, BRUECKNER L, et al. Promoter-intrinsic and local chromatin features determine gene repression in LADs［J］. Cell, 2019, 177(4): 852-864.

[5] [5] LEE S G, KIM J S, KIM H J, et al. Endothelial angiogenic activity and adipose angiogenesis is controlled by extracellular matrix protein TGFBI［J］. Scientific Reports, 2021, 11(1): 9644.

[6] [6] WEEN M P, OEHLER M K, RICCIARDELLIC. Transforming growth factor-beta-induced protein (TGFBI)/(βig-h3): a matrix protein with dual functions in ovarian cancer［J］. International Journal of Molecular Sciences, 2012, 13: 10461-10477.

[7] [7] RHODES D R, YU J, SHANKER K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform［J］. Neoplasia, 2004, 6(1): 1-6.

[8] [8] SANJAY N. Manual evaluation of tissue microarrays in a high-throughput research project: the contribution of Indian surgical pathology to the human protein atlas (HPA) project［J］. Proteomics, 2016, 16(8): 1266-1270.

[9] [9] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[10] [10] áDAM N, LAMCZKY A, MENYHART O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets［J］. Scientific Reports, 2018, 8(1): 9227.

[11] [11] VASAIKAR S V, STRAUB P, WANG J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types［J］. Nucleic Acids Research, 2018, 46(D1): D956-D963.

[12] [12] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses［J］. Neoplasia, 2017, 19(8): 649-658.

[13] [13] LI T, FAN J, WANG B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells［J］. Cancer Research, 2017, 77(21): e108-e110.

[14] [14] REBECCA S, MA J M, ZOU Z H, et al. Cancer statistics, 2014 ［J］. CA: A Cancer Journal for Clinicians, 2014, 64(1): 9-29.

[15] [15] RACEY C S, WITHROW D R, GESINK D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis［J］. Canadian Journal of Public Health, 2013, 104(2): e159-e166.

[16] [16] RUDRA G N, LOWE C, MATTIE M, et al. Discoidin domain receptor 1 contributes to tumorigenesis through modulation of TGFBI expression［J］. PLoS One, 2014, 9(11): e111515.

[17] [17] LEE M J, HEO S C, SHIN S H, et al. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI［J］. The International Journal of Biochemistry & Cell Biology, 2013, 45(8): 1869-1877.

[18] [18] ZHANG Y, WEN G, SHAO G, et al. TGFBI deficiency predisposes mice to spontaneous tumor development［J］. Cancer Research, 2009, 69(1): 37-44.

[19] [19] CHIAVARINA B, COSTANZA B, RONCA R, et al. Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis［J］. Theranostics, 2021, 11(4): 1626-1640.

[20] [20] MA C, RONG Y, RADILOFF D R, et al. Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation［J］. Genes & Development, 2008, 22(3): 308-321.

[21] [21] ZHANG H, DONG S, FENG J. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer［J］. Journal of Cellular Biochemistry, 2019, 120(6): 10767-10776.

[22] [22] LEBDAI S, VERHOEST G, PARIKH H, et al. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma［J］. Urologic Oncology, 2015, 33(2): 11-69.

[23] [23] DU G W, YAN X, CHEN Z, et al. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC)［J］. Aging, 2020, 12(9): 8484-8505.

[24] [24] RICCIARDELLI C, LOKMAN N A, WEEN M P, et al. Women in cancer thematic review: ovarian cancer-peritoneal cell interactions promote extracellular matrix processing［J］. Endocrine-Related Cancer, 2016, 23(11): T155-T168.

[25] [25] STEITZ A M, STEFFES A, FINKERNAGEL F, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C［J］. Cell Death & Disease, 2020, 11(4): 249.

[26] [26] LI B, WEN G, ZHAO Y, et al. The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression［J］. BMC Cancer, 2012, 12: 239.

[27] [27] WANG B J, CHI K P, SHEN R L, et al. TGFBI promotes tumor growth and is associated with poor prognosis in oral squamous cell carcinoma［J］. Journal of Cancer, 2019, 10(20): 4902-4912.

[28] [28] SATO T, MURAMATSU T, TANABE M, et al. Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line［J］. Cancer Science, 2018, 109(11): 3623-3633.

[29] [29] ZOU J, HUANG R, LI H, et al. Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells［J］. Cancer Management and Research, 2019, 11: 6995-7006.

[30] [30] GUO S K, SHEN M F, YAO H W, et al. Enhanced expression of TGFBI promotes the proliferation and migration of glioma cells［J］. Cellular Physiology Biochemistry, 2018, 49(3): 1097-1109.

[31] [31] SUZUKI M, YOKOBORI T, GOMBODORJ N, et al. High stromal?transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer［J］. Journal of Surgical Oncology, 2018, 118(6): 966-974.

[32] [32] OZAWA D, YOKOBORI T, SOHDA M, et al. TGFBI expression in cancer stromal cells is associated with poor prognosis and hematogenous recurrence in esophageal squamous cell carcinoma［J］. Annals of Surgical Oncology, 2016, 23(1): 282-289.

[33] [33] LAUDEN L, SIEWIERA J, BOUKOUACI W, et al. TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential［J］. The Journal of Investigative Dermatology, 2014, 134(6): 1675-1685.